Research

Energy balance

Persistence in the OMM-eligible cohort was 73.8%.

High persistence rates suggest good adherence to tirzepatide among eligible patients.

StrongSupportsmedium confidence
Persistence in the OMM-eligible cohort was 73.8 %;
Emily R. Hankosky et al. · Diabetes & Metabolism · 2025

Why this rating

Based on the retrospective observational study design with a substantial sample size.

Source

Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States

Emily R. Hankosky et al. · Diabetes & Metabolism · 2025

DOI 10.1016/j.diabet.2025.101636

cohort · n=4177Cited 11×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →